| Literature DB >> 30612740 |
Shuo Liu1, Simone Hausmann2, Scott Moore Carlson1, Mary Esmeralda Fuentes2, Joel William Francis1, Renjitha Pillai3, Shane Michael Lofgren2, Laura Hulea4, Kristofferson Tandoc4, Jiuwei Lu5, Ami Li6, Nicholas Dang Nguyen2, Marcello Caporicci2, Michael Paul Kim7, Anirban Maitra8, Huamin Wang9, Ignacio Ivan Wistuba10, John Anthony Porco11, Michael Cory Bassik6, Joshua Eric Elias12, Jikui Song5, Ivan Topisirovic4, Capucine Van Rechem3, Pawel Karol Mazur13, Or Gozani14.
Abstract
Increased protein synthesis plays an etiologic role in diverse cancers. Here, we demonstrate that METTL13 (methyltransferase-like 13) dimethylation of eEF1A (eukaryotic elongation factor 1A) lysine 55 (eEF1AK55me2) is utilized by Ras-driven cancers to increase translational output and promote tumorigenesis in vivo. METTL13-catalyzed eEF1A methylation increases eEF1A's intrinsic GTPase activity in vitro and protein production in cells. METTL13 and eEF1AK55me2 levels are upregulated in cancer and negatively correlate with pancreatic and lung cancer patient survival. METTL13 deletion and eEF1AK55me2 loss dramatically reduce Ras-driven neoplastic growth in mouse models and in patient-derived xenografts (PDXs) from primary pancreatic and lung tumors. Finally, METTL13 depletion renders PDX tumors hypersensitive to drugs that target growth-signaling pathways. Together, our work uncovers a mechanism by which lethal cancers become dependent on the METTL13-eEF1AK55me2 axis to meet their elevated protein synthesis requirement and suggests that METTL13 inhibition may constitute a targetable vulnerability of tumors driven by aberrant Ras signaling.Entities:
Keywords: METTL13; RAS; eEF1A; lung cancer; lysine methylation; pancreatic cancer; protein methylation; translation; translation elongation
Mesh:
Substances:
Year: 2019 PMID: 30612740 PMCID: PMC6499081 DOI: 10.1016/j.cell.2018.11.038
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582